FY2026 Earnings Estimate for FENC Issued By HC Wainwright

Adherex Technologies logo with Healthcare background
Image from MarketBeat Media, LLC.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Adherex Technologies in a report issued on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.34 per share for the year, up from their prior estimate of $0.21. HC Wainwright has a "Buy" rating and a $17.00 price target on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Adherex Technologies' Q4 2026 earnings at $0.15 EPS, Q1 2027 earnings at $0.17 EPS, Q2 2027 earnings at $0.23 EPS and FY2027 earnings at $1.00 EPS.

Several other equities research analysts also recently commented on the company. B. Riley Financial reiterated a "buy" rating and set a $19.00 target price (up from $18.00) on shares of Adherex Technologies in a report on Monday. Weiss Ratings upgraded shares of Adherex Technologies from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, November 13th. Wedbush boosted their price target on Adherex Technologies from $13.00 to $16.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Finally, Zacks Research raised Adherex Technologies from a "hold" rating to a "strong-buy" rating in a report on Thursday, November 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $17.50.

Get Our Latest Stock Analysis on Adherex Technologies

Adherex Technologies Stock Up 0.9%

Adherex Technologies stock opened at $13.45 on Friday. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.85. The firm has a market capitalization of $473.71 million, a P/E ratio of 190.43 and a beta of 1.29. The firm has a fifty day moving average of $10.75 and a 200-day moving average of $9.47.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.10 by $0.02. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. The firm had revenue of $19.61 million for the quarter, compared to analyst estimates of $18.87 million.

Insider Activity

In other news, CFO Robert Andrade sold 75,000 shares of the firm's stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $11.78, for a total transaction of $883,500.00. Following the completion of the transaction, the chief financial officer owned 217,675 shares in the company, valued at approximately $2,564,211.50. This trade represents a 25.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider directly owned 9,519 shares in the company, valued at $115,941.42. This represents a 55.76% decrease in their position. The SEC filing for this sale provides additional information. 10.73% of the stock is currently owned by insiders.

Adherex Technologies Company Profile

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

See Also

Earnings History and Estimates for Adherex Technologies (NASDAQ:FENC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Adherex Technologies Right Now?

Before you consider Adherex Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.

While Adherex Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines